Reverse transcription polymerase chain reaction

Collection Sites Makes Affordable FDA EUA Approved COVID-19 At-Home Testing Available Nationwide

Retrieved on:

Thursday, April 8, 2021

Articles, Life sciences, Branches of biology, Biotechnology, Laboratory techniques, Molecular biology, Polymerase chain reaction, Amplifiers, Clinical Laboratory Improvement Amendments, COVID-19, Reverse transcription polymerase chain reaction, Development of COVID-19 tests

The at-home test kits are available for purchase without a prescription by individuals through nationwide retail partners and by schools and businesses directly through the Collection Sites website.

Key Points:

The at-home test kits are available for purchase without a prescription by individuals through nationwide retail partners and by schools and businesses directly through the Collection Sites website.
Collection Sites test kits are developed by a leading infectious disease laboratory and are based on the FDA EUA authorized SARS-CoV-2 RT-PCR assay.
Collection Sites expert lab processing and testing fee of $89.99 can be covered by health insurance or credit card.
The company provides pop-up COVID-19 lab testing services, business-focused testing services, and at-home testing services, powered by CLIA-licensed laboratories.

Leading diagnostics laboratory in the Caribbean selects Molecular Biology Systems's NextGenPCR for SARS-CoV-2 testing

Retrieved on:

Wednesday, April 7, 2021

Molecular biology, Laboratory techniques, Biotechnology, Natural sciences, Biology, Life sciences, Polymerase chain reaction, Amplifiers, Reverse transcription polymerase chain reaction

FREDERICK, Md., April 7, 2021 /PRNewswire-PRWeb/ -- Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced that Aruba's Laboratorio di Servicio (LdS) has validated and implemented NextGenPCR for SARS-CoV-2 testing.

Key Points:

FREDERICK, Md., April 7, 2021 /PRNewswire-PRWeb/ -- Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced that Aruba's Laboratorio di Servicio (LdS) has validated and implemented NextGenPCR for SARS-CoV-2 testing.
"Last January, our lab Laboratorio di Servicio implemented the MBS' NextGenPCR solution for CoV2 screening, on Aruba."
"So, Laboratorio di Servicio is just one example of how NextGenPCR has delivered higher throughput by reducing time spent on RT-PCR."
Molecular Biology Systems, B.V., founded in 2015, is a life sciences solutions company based in Netherlands.

Baebies Announces FDA Acknowledgement of Emergency Use Notification for FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test – RT-PCR within 17 Minutes

Retrieved on:

Tuesday, April 6, 2021

Medical devices, FDA, Health, Infectious diseases, Other Health, General Health, Enzymes, Branches of biology, Chemistry, Laboratory techniques, Glucose-6-phosphate dehydrogenase, Jaundice, Reverse transcription polymerase chain reaction

The companys FINDER SARSCoV-2 Test is intended for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens with RT-PCR performed within 17 minutes.

Key Points:

The companys FINDER SARSCoV-2 Test is intended for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens with RT-PCR performed within 17 minutes.
We are launching the FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test to address the continued need for access to fast and accurate testing in health care facilities with high complexity laboratories.
Currently under FDA 510(k) review, FINDER tests for glucose-6-phosphate dehydrogenase (G6PD) deficiency , a genetic defect leading to anemia and severe jaundice.
The FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test have been validated but FDAs independent review of this validation is pending.

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Thursday, April 1, 2021

Other Health, Health, Science, Other Science, Oncology, Biotechnology, Laboratory techniques, Molecular biology, Natural sciences, Biology, Life sciences, Polymerase chain reaction, Reverse transcription polymerase chain reaction

These inducement stock options have a grant date of March 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points:

These inducement stock options have a grant date of March 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement stock options are subject to the terms and conditions of Biocepts Amended and Restated 2013 Equity Incentive Plan.
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers.
Additionally, Biocept is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

MatMaCorp Launches MYRTA, a New Hand-Held Real-Time PCR Device for POC and OTC Molecular Diagnostics

Retrieved on:

Tuesday, March 30, 2021

The device, called MYRTA (MY Real-Time Analyzer) was developed to provide portable, PCR-based molecular diagnostic solutions for human and animal health.

Key Points:

The device, called MYRTA (MY Real-Time Analyzer) was developed to provide portable, PCR-based molecular diagnostic solutions for human and animal health.
Real-time PCR is the primary method to reliably detect active infection of SARS-CoV-2 (the coronavirus that causes COVID-19) in patient samples.
This has resulted in PCR-based methods for OTC and POC devices being side-lined, regardless of the fact that real-time PCR is the benchmark by which other molecular tests are measured.
MatMaCorp successfully overcame these issues in the development of MYRTA, which can simultaneously conduct PCR amplification and rapid, real-time fluorescence detection.

XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Recent European Approval of 25-Minute COVID-19 PCR Test

Retrieved on:

Monday, March 29, 2021

Articles, Life sciences, Branches of biology, Biotechnology, Laboratory techniques, Molecular biology, COVID-19 testing, Polymerase chain reaction, Reverse transcription polymerase chain reaction, COVID-19, Draft:FELUDA, Draft:IGeneX

The audio press release covers XPhytos recent announcement highlighting the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system (Covid-ID Lab).

Key Points:

The audio press release covers XPhytos recent announcement highlighting the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system (Covid-ID Lab).
To hear the audio production, visit: https://www.nnw.fm/wAeDE
To read the original press release, visit: https://nnw.fm/BsSvD
Our test is one of the fastest PCR-based COVID-19 tests currently approved.
With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic, commented Hugh Rogers, CEO and Director of XPhyto.
Per the update, XPhyto is currently in discussions with various potential distribution and wholesale partners for its Covid-ID Lab, as well as potential licensees.

BioReference Laboratories Expands COVID-19 School Testing Program

Retrieved on:

Friday, March 26, 2021

Articles, Biotechnology, Laboratory techniques, Molecular biology, Life sciences, Natural sciences, Amplifiers, Hoffmann-La Roche, Polymerase chain reaction, COVID-19, Reverse transcription polymerase chain reaction

BioReference today announced the expansion of its COVID-19 school testing program.

Key Points:

BioReference today announced the expansion of its COVID-19 school testing program.
The Rockefeller Foundation announced an initiative to provide guidance on testing for K-12 schools and connect schools with laboratories and testing partners, including BioReference.
In support of President Biden's announcement to significantly increase funding for COVID-19 school testing, BioReference is prepared to expand our successful model to multiple other school districts around the country."
Programs specific for school testing can include RT-PCR lab-based testing as well as rapid PCR and antigen, depending on the school and/or district needs.

Clinix Health Announces ‘Turnkey’ Lab-Quality, Mobile Rapid PCR COVID-19 Testing Solutions in Ontario

Retrieved on:

Tuesday, March 23, 2021

Branches of biology, Biology, Life sciences, Biotechnology, Laboratory techniques, Molecular biology, COVID-19 testing, Polymerase chain reaction, Reverse transcription polymerase chain reaction

In all cases, Clinix Health only uses Health Canada-approved PCR testing solutions, providing 95 per cent accuracy for rapid testing and 99 per cent accuracy for traditional.

Key Points:

In all cases, Clinix Health only uses Health Canada-approved PCR testing solutions, providing 95 per cent accuracy for rapid testing and 99 per cent accuracy for traditional.
The diagnostic testing can occur at a Clinix Health clinic or at onsite at a business or workplace, allowing for both individualised, home-based testing and high volume, business-based, turnkey testing solutions.
The Clinix Health rapid testing options combine the best of both solutions providing rapid, mobile, and highly accurate results in about one hour using gold-standard RT-PCR technology.
Clinix Health provides testing services, including rapid COVID-19 testing for individuals and workplaces, and operates testing clinics in Toronto and Ottawa.

PathogenDx Applauded by Frost & Sullivan for Its Ultra-rapid COVID-19 Testing Platform, DetectX-Rv Test

Retrieved on:

Monday, March 22, 2021

Branches of biology, Natural sciences, Biology, Molecular biology, Laboratory techniques, Polymerase chain reaction, Biotechnology, Amplifiers, COVID-19 testing, Reverse transcription polymerase chain reaction, RT PCR, DNA microarray

PathogenDx adapted its unique testing platform by combining multiplexed end-point, real-time polymerase chain reaction (RT-PCR) with DNA microarray technology to enable testing for COVID-19 in people, in the air, and on contact surfaces.

Key Points:

PathogenDx adapted its unique testing platform by combining multiplexed end-point, real-time polymerase chain reaction (RT-PCR) with DNA microarray technology to enable testing for COVID-19 in people, in the air, and on contact surfaces.
"With an ultra-rapid sample-to-result testing turnaround time of four and a half hours, PathogenDx aims to simplify and expedite COVID-19 detection.
Furthermore, PathogenDx provides its environmental screening and monitoring EnviroX-Rv test for public facilities and buildings lacking ventilation.
Each year, Frost & Sullivan presents this award to the company that demonstrates uniqueness in developing and leveraging new technologies that deliver significant customer value.

PathogenDx Applauded by Frost & Sullivan for Its Ultra-rapid COVID-19 Testing Platform, DetectX-Rv Test

Retrieved on:

Monday, March 22, 2021

PathogenDx adapted its unique testing platform by combining multiplexed end-point, real-time polymerase chain reaction (RT-PCR) with DNA microarray technology to enable testing for COVID-19 in people, in the air, and on contact surfaces.

Key Points:

PathogenDx adapted its unique testing platform by combining multiplexed end-point, real-time polymerase chain reaction (RT-PCR) with DNA microarray technology to enable testing for COVID-19 in people, in the air, and on contact surfaces.
"With an ultra-rapid sample-to-result testing turnaround time of four and a half hours, PathogenDx aims to simplify and expedite COVID-19 detection.
Furthermore, PathogenDx provides its environmental screening and monitoring EnviroX-Rv test for public facilities and buildings lacking ventilation.
Each year, Frost & Sullivan presents this award to the company that demonstrates uniqueness in developing and leveraging new technologies that deliver significant customer value.